more

AbbVie (ABBV)

(Delayed Data from NYSE)

$161.59 USD

+0.31 (0.19%)

Updated May 14, 2024 04:00 PM ET

After-Market: $161.52 -0.07 (-0.04%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

Bottom 39% (153 out of 250)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for ABBV

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Revenue: Mavyret [$M]		1,430	1,541	1,710	1,830	2,893
Net Revenue: Hematologic Oncology...		5,915	6,577	5,408	5,314	--
Net Revenue: Immunology: Total [$...		26,136	28,924	25,284	22,153	19,571
Net Revenue: Neuroscience: Total ...		7,717	6,528	5,927	3,496	461
Net Revenue: Other Neuroscience: ...		276	475	685	539	--
Net Revenue: Other Aesthetics: To...		1,234	1,290	1,466	760	--
Net Revenue: Aesthetics: Total [$...		5,294	5,333	5,233	2,590	--
Net Revenue: Other Eye Care: Tota...		803	1,175	1,169	693	--
Net Revenue: Eye Care: Total [$M]		2,415	2,701	3,567	2,184	--
Net Revenue: Juvederm Collection:...		1,378	1,428	1,535	718	--
Net Revenue: Botox Therapeutic: T...		2,991	2,719	2,451	1,387	--
Net Revenue: Alphagan/Combigan: T...		272	346	529	326	--
Net Revenue: Lumigan/Ganfort [$M]		432	514	579	378	--
Net Revenue: Restasis: Total [$M]		436	666	1,290	787	--
Net Revenue: Linzess/Constella: T...		1,108	1,035	1,038	667	--
Net Revenue: Other Key Products: ...		3,806	3,854	5,489	--	--
Net Revenue: Eye Care: Ozurdex: T...		472	--	--	--	--
Net Revenue: Creon [$M]		1,268	--	1,191	1,114	1,041
Net Revenue: Humira [$M]		14,404	19,769	20,694	19,832	19,169
Net Revenue: Immunology: Skyrizi:...		7,763	5,165	2,939	1,590	355
Net Revenue: Rinvoq: Total [$M]		3,969	2,522	1,651	731	47
Net Revenue: Imbruvica [$M]		3,596	4,568	5,408	5,314	4,674
Net Revenue: Venclexta [$M]		2,288	2,009	1,820	1,337	792
Net Revenue: Botox Cosmetic: Tota...		2,682	2,615	2,232	1,112	--
Net Revenue: Vraylar: Total [$M]		2,759	2,038	1,728	951	--
Net Revenue: Duodopa [$M]		468	458	511	494	461
Net Revenue: Ubrelvy: Total [$M]		815	680	552	125	--
Net Revenue: Qulipta: Total [$M]		408	--	--	--	--
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Revenue: Mavyret: US [$M]		659	755	754	785	1,473
Net Revenue: Mavyret: Internation...		771	786	956	1,045	1,420
Net Revenue: Immunology: Total US...		21,737	24,897	21,087	18,150	15,222
Net Revenue: Immunology: Total In...		4,399	4,027	4,197	4,003	4,349
Net Revenue: Hematologic Oncology...		3,778	4,435	5,255	5,109	4,351
Net Revenue: Hematologic Oncology...		2,137	2,142	1,973	1,542	1,115
Net Revenue: Neuroscience: U.S [$...		6,790	5,681	5,061	2,862	97
Net Revenue: Neuroscience: Intern...		927	847	866	634	364
Net Revenue: Other Neuroscience: ...		254	456	667	528	--
Net Revenue: Other Neuroscience: ...		22	19	18	11	--
Net Revenue: Other Aesthetics: U....		1,060	1,122	1,268	666	--
Net Revenue: Other Aesthetics: In...		174	168	198	94	--
Net Revenue: Aesthetics: U.S [$M]		3,249	3,324	3,350	1,671	--
Net Revenue: Aesthetics: Internat...		2,045	2,009	1,883	919	--
Net Revenue: Other Eye Care: U.S ...		433	538	523	305	--
Net Revenue: Other Eye Care: Inte...		370	637	646	388	--
Net Revenue: Eye Care: U.S [$M]		1,252	1,603	2,403	1,448	--
Net Revenue: Eye Care: Internatio...		1,163	1,098	1,164	736	--
Net Revenue: Ubrelvy: U.S [$M]		803	680	552	125	--
Net Revenue: Ubrelvy: Internation...		12	--	0	0	--
Net Revenue: Botox Cosmetic: US [...		1,670	1,654	1,424	687	--
Net Revenue: Botox Cosmetic: Inte...		1,012	961	808	425	--
Net Revenue: Juvederm Collection:...		519	548	658	318	--
Net Revenue: Juvederm Collection:...		859	880	877	400	--
Net Revenue: Botox Therapeutic: U...		2,476	2,255	2,012	1,155	--
Net Revenue: Botox Therapeutic: I...		515	464	439	232	--
Net Revenue: Alphagan/Combigan: U...		121	202	373	223	--
Net Revenue: Alphagan/Combigan: I...		151	144	156	103	--
Net Revenue: Lumigan/Ganfort: US ...		173	242	273	165	--
Net Revenue: Lumigan/Ganfort: Int...		259	272	306	213	--
Net Revenue: Restasis: US [$M]		382	621	1,234	755	--
Net Revenue: Restasis: Internatio...		54	45	56	32	--
Net Revenue: Vraylar: US [$M]		2,755	2,037	1,728	951	--
Net Revenue: Vraylar: Internation...		4	1	0	0	--
Net Revenue: Linzess/Constella: U...		1,073	1,003	1,006	649	--
Net Revenue: Linzess/Constella: I...		35	32	32	18	--
Net Revenue: Other Key Products: ...		3,000	3,036	4,322	--	--
Net Revenue: Other Key Products: ...		806	818	1,167	--	--
Net Revenue: Eye Care: Ozurdex: U...		143	--	--	--	--
Net Revenue: Eye Care: Ozurdex: R...		329	--	--	--	--
Geographic Revenues: United State...		41,883	45,713	43,510	34,879	23,907
Net Revenue: Creon: US [$M]		1,268	1,278	1,191	1,114	1,041
Net Revenue: Duodopa: Internation...		371	363	409	391	364
Net Revenue: Duodopa: US [$M]		97	95	102	103	97
Geographic Revenues: Internationa...		12,435	12,341	--	10,925	9,359
Net Revenue: Humira: US [$M]		12,160	18,619	17,330	16,112	14,864
Net Revenue: Humira: Internationa...		2,244	2,618	3,364	3,720	4,305
Net Revenue: Immunology: Skyrizi:...		6,753	4,484	2,486	1,385	311
Net Revenue: Immunology: Skyrizi:...		1,010	681	453	205	44
Net Revenue: Rinvoq: US [$M]		2,824	1,794	1,271	653	47
Net Revenue: Rinvoq: Internationa...		1,145	728	380	78	--
Net Revenue: Imbruvica: US [$M]		2,665	3,426	4,321	4,305	3,830
Net Revenue: Imbruvica: Internati...		931	1,142	1,087	1,009	844
Net Revenue: Venclexta: US [$M]		1,087	1,009	934	804	521
Net Revenue: Venclexta: Internati...		1,201	1,000	886	533	271

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Net Revenue: Mavyret [$M]		349	309	370	387	364
Net Revenue: Hematologic Oncology...		1,543	1,509	1,512	1,478	1,416
Net Revenue: Immunology: Total [$...		5,371	6,953	6,783	6,813	5,587
Net Revenue: Neuroscience: Total ...		1,965	2,094	2,043	1,885	1,695
Net Revenue: Other Neuroscience: ...		74	66	61	70	79
Net Revenue: Other Aesthetics: To...		319	319	298	331	286
Net Revenue: Aesthetics: Total [$...		1,249	1,371	1,239	1,384	1,300
Net Revenue: Other Eye Care: Tota...		200	181	207	215	200
Net Revenue: Eye Care: Total [$M]		538	585	605	617	608
Net Revenue: Juvederm Collection:...		297	334	321	368	355
Net Revenue: Botox Therapeutic: T...		748	776	748	748	719
Net Revenue: Alphagan/Combigan: T...		59	66	70	65	71
Net Revenue: Lumigan/Ganfort [$M]		91	92	91	119	130
Net Revenue: Restasis: Total [$M]		57	128	117	99	92
Net Revenue: Linzess/Constella: T...		266	283	288	278	259
Net Revenue: Other Key Products: ...		900	968	963	947	928
Net Revenue: Eye Care: Ozurdex: T...		131	118	120	119	115
Net Revenue: Creon [$M]		285	376	305	282	305
Net Revenue: Humira [$M]		2,270	3,304	3,547	4,012	3,541
Net Revenue: Immunology: Skyrizi:...		2,008	2,394	2,126	1,883	1,360
Net Revenue: Rinvoq: Total [$M]		1,093	1,255	1,110	918	686
Net Revenue: Imbruvica [$M]		838	903	908	907	878
Net Revenue: Venclexta [$M]		614	589	590	571	538
Net Revenue: Botox Cosmetic: Tota...		633	718	620	685	659
Net Revenue: Vraylar: Total [$M]		694	789	751	658	561
Net Revenue: Duodopa [$M]		115	115	118	117	118
Net Revenue: Ubrelvy: Total [$M]		203	234	233	196	152
Net Revenue: Qulipta: Total [$M]		131	114	132	96	66
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Net Revenue: Mavyret: US [$M]		144	128	167	193	171
Net Revenue: Mavyret: Internation...		205	181	203	194	193
Net Revenue: Immunology: Total US...		4,152	5,774	5,696	5,731	4,536
Net Revenue: Immunology: Total In...		1,219	1,179	1,087	1,082	1,051
Net Revenue: Hematologic Oncology...		967	971	973	931	903
Net Revenue: Hematologic Oncology...		576	538	539	547	513
Net Revenue: Neuroscience: U.S [$...		1,714	1,861	1,817	1,649	1,463
Net Revenue: Neuroscience: Intern...		251	233	226	236	232
Net Revenue: Other Neuroscience: ...		61	59	55	65	75
Net Revenue: Other Neuroscience: ...		13	7	6	5	4
Net Revenue: Other Aesthetics: U....		281	275	255	284	246
Net Revenue: Other Aesthetics: In...		38	44	43	47	40
Net Revenue: Aesthetics: U.S [$M]		776	884	759	829	777
Net Revenue: Aesthetics: Internat...		473	487	480	555	523
Net Revenue: Other Eye Care: U.S ...		105	99	114	110	110
Net Revenue: Other Eye Care: Inte...		95	82	93	105	90
Net Revenue: Eye Care: U.S [$M]		227	314	310	309	319
Net Revenue: Eye Care: Internatio...		311	271	295	308	289
Net Revenue: Ubrelvy: U.S [$M]		197	229	230	194	150
Net Revenue: Ubrelvy: Internation...		6	5	3	2	2
Net Revenue: Botox Cosmetic: US [...		389	453	388	420	409
Net Revenue: Botox Cosmetic: Inte...		244	265	232	265	250
Net Revenue: Juvederm Collection:...		106	156	116	125	122
Net Revenue: Juvederm Collection:...	--	191	178	205	243	233
Net Revenue: Botox Therapeutic: U...		611	649	626	614	587
Net Revenue: Botox Therapeutic: I...		137	127	122	134	132
Net Revenue: Alphagan/Combigan: U...		15	31	30	32	28
Net Revenue: Alphagan/Combigan: I...		44	35	40	33	43
Net Revenue: Lumigan/Ganfort: US ...		29	31	28	51	63
Net Revenue: Lumigan/Ganfort: Int...		62	61	63	68	67
Net Revenue: Restasis: US [$M]		44	117	104	82	79
Net Revenue: Restasis: Internatio...		13	11	13	17	13
Net Revenue: Vraylar: US [$M]		692	788	750	657	560
Net Revenue: Vraylar: Internation...		2	1	1	1	1
Net Revenue: Linzess/Constella: U...		257	274	279	269	251
Net Revenue: Linzess/Constella: I...		9	9	9	9	8
Net Revenue: Other Key Products: ...		686	778	751	744	727
Net Revenue: Other Key Products: ...		214	190	212	203	201
Net Revenue: Eye Care: Ozurdex: U...		34	36	34	34	39
Net Revenue: Eye Care: Ozurdex: R...		97	82	86	85	76
Geographic Revenues: United State...		9,041	11,110	10,852	10,720	9,201
Net Revenue: Creon: US [$M]		285	376	305	282	305
Net Revenue: Duodopa: Internation...		25	92	93	93	93
Net Revenue: Duodopa: US [$M]		90	23	25	24	25
Geographic Revenues: Internationa...		3,269	3,191	3,075	3,145	3,024
Net Revenue: Humira: US [$M]		1,771	2,740	3,020	3,452	2,948
Net Revenue: Humira: Internationa...		499	564	527	560	593
Net Revenue: Immunology: Skyrizi:...		1,656	2,105	1,875	1,634	1,139
Net Revenue: Immunology: Skyrizi:...		352	289	251	249	221
Net Revenue: Rinvoq: US [$M]		725	929	801	645	449
Net Revenue: Rinvoq: Internationa...		368	326	309	273	237
Net Revenue: Imbruvica: US [$M]		610	683	678	666	638
Net Revenue: Imbruvica: Internati...		228	220	230	241	240
Net Revenue: Venclexta: US [$M]		281	276	281	265	265
Net Revenue: Venclexta: Internati...		333	313	309	306	273

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators